Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
| Technology Name (St. Jude Reference #) |
Molecular Cloning of the Equilibrative, NBMPR-insensitive Nucleosides Transporter (SJ-97-0004) |
| Description | This invention provides nucleic acids and polypeptides to ENT2, a human equilibrative, NBMPR-insensitive nucleoside transport protein that transports nucleosides across the plasma membrane through a facilitated diffusion process. ENT2 may be used in structure activity studies to improve the uptake of nucleoside analog drugs into cells. In addition, this invention may also be used to introduce ENT2 into normal cells; thus, providing protection to antifolate and NBMPR combination therapy in healthy cells while allowing the drugs to act in tumor cells. |
| Keywords | Transporter, gene therapy, antifolate drug clearance |
| Granted Patents or Published Applications | U.S. Patent #6,130,065; 6,423,829 |
| Related Scientific References |
Patel, DH, et al, "Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells" Blood 95:2356-63 (2000). Crawford, CR, at al, "Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line" J Biol Chem. 273:5288-93 (1998). |
| Licensing Opportunities | We are seeking licensees in all fields for the development of this technology. |
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: June 2006
